stockportfolio.pro
Stocks / ACAD vs VCYT
ACAD vs VCYT
ACADIA Pharmaceuticals Inc. and Veracyte, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ACADIA Pharmaceuticals Inc. (ACAD) | Veracyte, Inc. (VCYT) | |
|---|---|---|
| Market cap | $3.7B | $3.9B |
| Revenue (latest FY) | $1.07B | $517.14M |
| Net income (latest FY) | $391.00M | $66.35M |
| Revenue growth (5y CAGR) | 19.4% | 34.5% |
| Net margin | 36.5% | 12.8% |
| Return on equity | 31.9% | 5.1% |
| P/E ratio | 9.7 | 44.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 2 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ACAD — free Open VCYT — freeFrequently asked questions
Which is bigger, ACAD or VCYT?
Veracyte, Inc. is larger by market capitalization — $3.9B versus $3.7B.
Which grows faster, ACAD or VCYT?
Over the last five fiscal years, Veracyte, Inc. grew revenue faster — 34.5%/yr versus 19.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.